Vrije Universiteit Brussel

 

Publications on Multiple Myeloma

Evidence of a role for RANKL in the development of myeloma bone disease
  • Evidence of a role for RANKL in the development of myeloma bone disease.

    De Leenheer, E, Mueller, GS, Vanderkerken, K, Croucher, PI.

    Curr Opin Pharmacol 4 (4), 340-6, 2004.

    Abstract:
    Multiple myeloma is associated with the development of a devastating bone disease mediated by increased osteoclastic activity. The ligand for receptor activator of nuclear factor-kappaB (RANKL) plays a critical role in normal osteoclast biology and is abnormally regulated in myeloma. Targeting this system with recombinant decoy receptor, osteoprotegerin, or soluble forms of the receptor activator of nuclear factor-kappaB is able to prevent myeloma bone disease in pre-clinical models. Intriguingly, inhibiting osteoclast formation and bone resorption, and altering the bone marrow microenvironment, results in an indirect anti-myeloma effect.

 

Back to top

  ©2004-2006 • HEIM • Vrije Universiteit Brussel • Faculteit Geneeskunde & Farmacie • Laarbeeklaan 103 • 1090 Jette • Tel.: (+32)-(0)2-477.44.06 • heim@vub.ac.be